HER2 Vaccine for Locally Advanced Breast Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

March 31, 2030

Conditions

Breast CancerHER2-positive Breast Cancer

Interventions

DRUG

HER2 Vaccine

MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines

Trial Locations (1)

RECRUITING

Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianapolis

All Listed Sponsors

lead

Pravin T.P Kaumaya

OTHER

NCT06949410 - HER2 Vaccine for Locally Advanced Breast Cancer | Biotech Hunter | Biotech Hunter